Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
CAS:154229-19-3
Molecular Formula:C24H31NO
Alias
More Information
(3Beta)-17-(3-Pyridinyl)-Androsta-5,16-Dien-3-Ol; Androsta-5,16-Dien-3-Ol, 17-(3-Pyridinyl)-, (3Beta)-; Cb 7598; Cb-7598; Unii-G819A456D0; Abiraterone(Cb-7598); 17-(3-Pyridyl)Androsta-5,16-Dien-3Beta-Ol; Cb7598; Zytiga
Brief Introduction
Abiraterone acetate (INN, USAN, BAN, JAN) (brand names Zytiga, Abiratas, Abretone, Abirapro) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. In addition, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.
Suppliers
View More Vendors (4） >
CAS:154361-50-9
Molecular Formula:C15H22FN3O6
Alias
More Information
Pentyl [1-(3,4-Dihydroxy-5-Methyl-Oxolan-2-Yl)-5-Fluoro-2-Oxo-Pyrimidin-4-Yl]Aminoformate; Xeloda; Capecytabine; Ro 09-1978; Captabin; 5'-Deoxy-5-Fluoro-N-[(Pentyloxy)Carbonyl]Cytidine; Ro-9-1978; 5'-Deoxy-5-Fluoro-N4-[(Pentyloxy)Carbonyl]Cytidine; Cpecitabine; Capecitibine; Ro 09-1978/000; Capcitabine; 5'-Deoxy-5-Fluorocytisine; Pentyl (1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-Methyltetrahydrofuran-2-Yl)-5-Fluoro-2-Oxo-1,2-Dihydr
Brief Introduction
Capecitabine, an antimetabolite fluoropyrimidine deoxynucleoside carbamate that can be converted to 5-FU in vivo, was developed by Roche under the trade name hiloda and is able to inhibit cell division and interfere with RNA and protein synthesis. For further treatment of paclitaxel and advanced primary or metastatic breast cancer including patients refractory to chemotherapeutic regimens with anthracyclines. It is mainly used for the treatment of advanced primary or metastatic breast, rectal, colon and gastric cancer.
Suppliers
View More Vendors (4） >
Alias
More Information
Mixed Tocopherols
Brief Introduction
Using mixed tocopherol concentrate as raw material, various specifications of mixed natural vitamin E are purified and compounded through chemical processes such as pretreatment, adsorption separation and molecular distillation.
Suppliers
View More Vendors (4） >
Tocopherol content: 70% - 90%
/
Food Grade
10kg
/
Plastic Drum
Alias
More Information
Tasigna; Nilotinib (Amn-107); Its Intermediates; Nilotinib For Research; Nilotinib(Amn 107); Nilotinib,Amn107,Tasigna; Amn 107; Nilotinib D6
Brief Introduction
Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
Suppliers
View More Vendors (3） >
Yangzhou Qinyuan Pharmaceutical Technology Co.,Ltd.
99.5%
/
-
CAS:656247-18-6
Molecular Formula:C33H39N5O7S
Alias
More Information
3-Z-[1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Methyl-Amino)-Anilino)-1-Phenyl-Methylene]-6-Methoxycarbonyl-2-Indolinone Monoethanesulphonate; Ethanesulfonic Acid - Methyl (3Z)-3-{[(4-{Methyl[(4-Methyl-1-Pipe Razinyl)Acetyl]Amino}Phenyl)Amino](Phenyl)Methylene}-2-Oxo-6-Indo Linecarboxylate (1:1); Methyl (3Z)-3-[({4-[N-Methyl-2-(4-Methylpiperazin-1-Yl)Acetamido]Phenyl}Amino)(Phenyl)Methylidene]-2-Oxo-2,3-Dihydro-1H-Indole-6-Carboxylate Ethanesulfonate Salt; 3-Z-[1-(4-(N-((4-Methyl-Piperazin-1-Yl)-Methylcarbonyl)-N-Methyl-Amino)-Anilino)-1-Phenyl-Methylene]-6-Methoxycarbonyl-2-Indolinone Monoethanesulfonate Salt; (3S,5S)-3,5-Bis[[(1,1-Dimethylethyl)Dimethylsilyl]Oxy]-1-Hydroxy-Cyclohexanecarboxylic Acid Methyl Ester
Brief Introduction
Nitanib ethylsulfonate is a small molecule inhibitor of multi receptor tyrosine kinase and non receptor tyrosine kinase. In 2014, it was approved by FDA for the first time, and was developed and sold by bringer Ingelheim company for the first time. It has been approved by the US Food and Drug Administration (FDA), the European Drug Administration (EMA) and the agency for drugs and medical devices (PMDA) for the treatment of idiopathic pulmonary fibrosis, and by EMA for non-small cell lung cancer.
Suppliers
View More Vendors (3） >
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!